Pyng Medical Corp

Saving lives by saving time through innovation in resuscitation®

Pyng Medical Corp. Announces Changes To Management

November 12th, 2009

Vancouver, BC – Pyng Medical Corporation (TSX-V: PYT) (“Pyng Medical” or the “Company”) today announced that the Company has appointed George G. Dorin as the CFO effective November 5, 2009. Mr. Dorin is a Chartered Accountant and holds a Masters Degree in Finance from the London School of Economics in England. He has been a Chief Financial Officer and Vice President Finance for several private and public companies over the last 15 years.

Mr. Dorin’s career in finance spans over twenty-five years. Most recently, he has been providing corporate finance and financial management advisory services to various industrial companies through his own firm, CANUS Capital Corporation.

“George has had a significant amount of financial management experience with internationally focused companies,” stated the CEO Robert (Bob) Di Silvio. “On behalf of the board and management of Pyng Medical, I would like to welcome him to his new role as CFO with Pyng Medical.”

About Pyng Medical Corp.
Pyng is a leader in resuscitation innovation with simple-to-use and highly effective products including the FAST1® Intraosseous Infusion System, the FASTxTM Sternal Intraosseous Device, T-POD® Pelvic Stabilizer, and MAT® Tourniquet. The Company is awaiting FDA approval of the CRIC Cricothyrotomy System which is currently under final development. The Company plans to submit an application for FDA approval of the FASTxTM System, which is currently still under development.

For further information, please contact:
PYNG MEDICAL CORPORATION
George Dorin, Acting Chief Financial Officer
Tel. No. (604) 696-6388

For further company information please access our website: www.Pyng.com.

For More Information

George Dorin
Pyng Medical Corp.
(604) 303-7964
www.pyng.com

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.